Literature DB >> 7749041

Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan.

T Horiki1, H Inoko, J Moriuchi, Y Ichikawa, S Arimori.   

Abstract

HLA class II alleles in the DQA1, DQB1, DRB1, and DPB1 genes were investigated in Japanese patients with myasthenia gravis (MG) by digestion of polymerase chain reaction amplified DNAs with allele specific restriction endonucleases (PCR-RFLP). A significantly higher frequency of DQB1*03, which includes *0301, *0302, *0303 and determines the serological DQ3 specificity, was observed in female patients less than 30 years in age at onset of disease compared with healthy controls (90.5 vs. 53.2%). This study also confirms the high incidence of DPB1*0201 in early-onset female patients compared to the controls (85.7 vs. 40.3%). Moreover, 81.0% of the early onset female patients were found to carry both DQB1*03 and DPB1*0201, compared to 17.7% of the controls. Since DQB1*03 and DPB1*0201 are not in linkage disequilibrium, both these alleles are supposed to be synergistically involved in disease development in early-onset female MG. In contrast, no obvious association of HLA-DQA1, DQB1, DRB1 and DPB1 alleles with either late-onset patients or patients with thymoma was observed. Clearly, the genetic background of Japanese females with early onset MG is different from that of other patients with MG.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7749041     DOI: 10.3109/08916939409008008

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  6 in total

1.  HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.

Authors:  Marcel van Lith; Rosanna M McEwen-Smith; Adam M Benham
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

2.  HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy.

Authors:  Hanna M Ollila; Jean-Marie Ravel; Fang Han; Juliette Faraco; Ling Lin; Xiuwen Zheng; Giuseppe Plazzi; Yves Dauvilliers; Fabio Pizza; Seung-Chul Hong; Poul Jennum; Stine Knudsen; Birgitte R Kornum; Xiao Song Dong; Han Yan; Heeseung Hong; Cristin Coquillard; Joshua Mahlios; Otto Jolanki; Mali Einen; Isabelle Arnulf; Sophie Lavault; Birgit Högl; Birgit Frauscher; Catherine Crowe; Markku Partinen; Yu Shu Huang; Patrice Bourgin; Outi Vaarala; Alex Désautels; Jacques Montplaisir; Steven J Mack; Michael Mindrinos; Marcelo Fernandez-Vina; Emmanuel Mignot
Journal:  Am J Hum Genet       Date:  2015-01-08       Impact factor: 11.025

3.  HLA-DQB1*05:02, *05:03, and *03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort.

Authors:  Maria Salvado; Jose Luis Caro; Cecilia Garcia; Francesc Rudilla; Laura Zalba-Jadraque; Eva Lopez; Elia Sanjuan; Josep Gamez; Jose Manuel Vidal-Taboada
Journal:  Neurol Sci       Date:  2022-05-06       Impact factor: 3.830

4.  IDENTICAL TWIN SISTERS WITH CLOSE ONSET OF GRAVES' DISEASE AND WITH MULTIPLE HLA SUSCEPTIBILITY ALLELES FOR GRAVES' DISEASE.

Authors:  T Matsuo; Y Ushiroda
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Jan-Mar       Impact factor: 0.877

5.  Variation in the Human Leukocyte Antigen system and risk for endemic Burkitt lymphoma in northern Uganda.

Authors:  Samuel Kirimunda; Murielle Verboom; Isaac Otim; Mark Ssennono; Ismail D Legason; Hadijah Nabalende; Martin D Ogwang; Patrick Kerchan; Tobias Kinyera; Ivan Mwebaza; Moses Joloba; Leona W Ayers; Steven J Reynolds; Kishor Bhatia; Olusegun O Onabajo; Michael Hallensleben; Robert J Biggar; Ludmila Prokunina-Olsson; James J Goedert; Rainer Blasczyk; Sam M Mbulaiteye
Journal:  Br J Haematol       Date:  2020-02-18       Impact factor: 8.615

6.  Autoimmune polyglandular syndrome type 2 and autoimmune hepatitis with thymoma-associated myasthenia gravis: case report.

Authors:  Hidefumi Inaba; Hiroyuki Ariyasu; Hiroshi Iwakura; Chiaki Kurimoto; Yoko Ueda; Shinsuke Uraki; Ken Takeshima; Yasushi Furukawa; Shuhei Morita; Yoshiaki Nakayama; Takuya Ohashi; Hidefumi Ito; Yoshiharu Nishimura; Takashi Akamizu
Journal:  BMC Endocr Disord       Date:  2020-04-07       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.